Prophylactic use of G-CSF should probably be initiated or resumed in critically ill patients with neutropenia or requiring cancer chemotherapy with expected medullary toxicity (Grade 2+, weak agreement). The gene discussed is CSF3; the disease is Decreased total neutrophil count.